Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460084 | 1.00 | AVPR2 (0.51) | AVPR2AVPR1A | |
| SCHEMBL256612 | 1.00 | AVPR2 (0.51) | AVPR2AVPR1A | |
| SCHEMBL19575114 | 0.87 | AVPR2 (0.41) | AVPR2AVPR1A | |
| SCHEMBL8232792 | 0.80 | APOBEC3G (0.48) | AVPR2AVPR1A | |
| SCHEMBL168320 | 0.79 | APOBEC3G (0.45) | AVPR2AVPR1A | |
| SCHEMBL165618 | 0.78 | APOBEC3G (0.44) | AVPR2AVPR1A | |
| SCHEMBL19265137 | 0.77 | AVPR2 (0.48) | AVPR2AVPR1A | |
| SCHEMBL22319505 | 0.77 | APOBEC3G (0.39) | AVPR2AVPR1A | |
| SCHEMBL22319508 | 0.77 | APOBEC3G (0.39) | AVPR2AVPR1A | |
| Water SCHEMBL2512796 | 0.77 | APOBEC3G (0.43) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202895-B2 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-19 | — | — | US | claimed |
| WO-2022112213-A1 | CRYSTALLINE FORMS OF 3-[[3-(4-CHLOROPHENYL)-5-OXO-4-((2S)-3,3,3-TRIFLUORO- 2-HYDROXYPROPYL)-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-1-YL]METHYL]-1-[3- (TRIFLUOROMETHYL)PYRIDIN-2-YL]-1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-02 | — | — | WO | disclosed |
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-11230540-B2 | Substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-25 | — | — | US | disclosed |
| US-11230540-B2 | Substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-25 | — | — | US | disclosed |
| WO-2021259852-A1 | PROCESS FOR PREPARING 5-(ALKOXYCARBONYL)-AND 5-(CARBOXAMIDE)-1-ARYL-1,2,4-TRIAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-30 | — | — | WO | disclosed |
| US-11091463-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-17 | — | — | US | disclosed |
| CN-113105403-A | Process for preparing 5-hydroxyalkyl-substituted 1-phenyl-1, 2, 4-triazole derivatives | 拜耳制药股份公司 | 2021-07-13 | — | — | CN | disclosed |
| US-20210179590-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | disclosed |
| EP-2408754-A1 | Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-25 | — | — | EP | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011023703-A1 | HETEROCYCLIC-SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | WO | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010105750-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179590-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | GLS, TNNI3, CYP11B2 | AVPR2 1574/4885AVPR1A 2827/4885 |
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | GLS, TNNI3, NAT1 | AVPR2 1052/4885AVPR1A 1988/4885 |
| US-11230540-B2 | Substituted triazole derivatives and uses thereof | GLS, TNNI3, CYP11B2 | AVPR2 1574/4885AVPR1A 2827/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | AVPR2 2370/4885AVPR1A 3230/4885 |
| US-11091463-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | AADAC, GLS, PDXK | AVPR2 1068/4885AVPR1A 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.